← Back to Search

NMDA receptor antagonist

Ketamine plus usual care for Traumatic Injury (KAPT Trial)

Phase 4
Waitlist Available
Led By John P Harvin, MD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult trauma patients
Admission to Shock Trauma ICU (STICU) or Surgical Intermediate Unit (SIMU)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months post admission
Awards & highlights

KAPT Trial Summary

This trial looks at whether adding Ketamine to standard care can help manage pain in trauma patients, and how well patients tolerate this treatment.

Eligible Conditions
  • Traumatic Injury
  • Pain
  • Opioid Use Disorder

KAPT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

KAPT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months post admission
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months post admission for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Average Daily Opioid Use as Measured by the Morphine Milligram Equivalents (MME) Per Day
Secondary outcome measures
Duration of Ketamine Drip
Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Anxiety/Depression)
Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Current Health)
+22 more

KAPT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ketamine plus Usual careExperimental Treatment1 Intervention
Group II: Usual careActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine plus usual care
2020
Completed Phase 4
~310

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
902 Previous Clinical Trials
320,634 Total Patients Enrolled
John P Harvin, MDPrincipal InvestigatorThe University of Texas Health Science Center, Houston

Frequently Asked Questions

~65 spots leftby Mar 2025